4 results match your criteria: "Yale University and Yale Comprehensive Cancer Center[Affiliation]"
Beyond HMAs: Novel Targets and Therapeutic Approaches.
Semin Hematol
December 2024
Department of Internal Medicine, Section of Hematology, Yale University and Yale Comprehensive Cancer Center, New Haven, Connecticut.
Article Synopsis
- * Treatment for lower-risk MDS focuses on improving quality of life and may include therapies like erythropoiesis-stimulating agents and new medications like imetelstat, while higher-risk MDS often utilizes hypomethylating agents as standard care, with ongoing research into combination therapies.
- * Despite advancements in treatment options, especially for higher-risk MDS, challenges remain due to limited effective therapies after initial treatment failures, highlighting the need for new drug developments that could change current treatment approaches.
The importance of erythroblast enumeration in myeloid neoplasia.
Ann Hematol
February 2017
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Comparing the prognostic value of risk stratifying models for patients with lower-risk myelodysplastic syndromes: Is one model better?
Am J Hematol
November 2015
Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida.
Some patients classified as having lower-risk (LR)-disease by the International Prognostic Scoring System (IPSS) fare more poorly than predicted. We examined the prognostic utility of IPSS, the MD Anderson LR-Prognostic System (LR-PSS), and the revised IPSS (IPSS-R) in a large cohort of patients classified as having IPSS LR-MDS in the MDS Clinical Research Consortium database. Actual overall survival (OS) was assessed in patients with IPSS LR-MDS (i.
View Article and Find Full Text PDFMolecular Testing in Myelodysplastic Syndromes for the Practicing Oncologist: Will the Progress Fulfill the Promise?
Oncologist
September 2015
Section of Hematology, Department of Internal Medicine, Yale University and Yale Comprehensive Cancer Center, New Haven, Connecticut, USA
Unlabelled: Myelodysplastic syndromes (MDS) are heterogeneous hematopoietic neoplasms that are driven by somatically acquired genetic mutations and epigenetic alterations. Accurate risk stratification is essential for delivery of risk-adaptive therapeutic interventions. The current prognostic tools sum the impact of clinical, pathologic, and laboratory parameters.
View Article and Find Full Text PDF